Compare GEVO & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | MOBI |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.8M | 383.0M |
| IPO Year | 2010 | 2026 |
| Metric | GEVO | MOBI |
|---|---|---|
| Price | $1.54 | $10.61 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.58 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 91.8K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $711,000.00 | N/A |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $10.34 |
| 52 Week High | $2.97 | $15.19 |
| Indicator | GEVO | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 35.54 |
| Support Level | $1.40 | N/A |
| Resistance Level | $1.57 | $12.33 |
| Average True Range (ATR) | 0.09 | 1.08 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 40.00 | 4.50 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.